Natera's Stronghold in Cancer Recurrence Tests Prompts Wood's Ark to Expand Stake Natera, an Austin based biotechnology company, has solidified its position as a leader in the market for measurable residual disease (MRD) technology.
The company's $28. 4 billion valuation surpasses that of Illumina, a leading gene sequencing firm, thanks in part to the potential of MRD technology to revolutionize cancer treatment.
At the heart of Natera's success is Signatera, its flagship product that uses personalized MRD blood tests to detect cancer recurrence.